Drugs Made in America Acquisition II FY26 Q2 net income turns to profit at $4.4 million
DMII•Quarterly and six-month results
Drugs Made in America Acquisition II posted net income of $4.4 million for the quarter ended June 30, 2026.
General and administrative costs totaled $112,227, offset by $4.51 million of interest income from the trust account.
Six-month net income rose to $8.73 million, reflecting $8.95 million of trust interest income and a $30,000 credit-loss recovery.
Cash was $174,974 at June 30, 2026, up from $223 at Dec. 31, 2025.
